MedTrace Logo

Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

NCT01724385 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-04-26

No results posted yet for this study

Summary

To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).

Conditions

  • Vitreous Hemorrhage
  • Proliferative Diabetic Retinopathy

Interventions

DRUG

intravitreal injection of bevacizumab

intravitreal injection of bevacizumab

Sponsors & Collaborators

  • Khon Kaen University

    lead OTHER

Principal Investigators

  • Suthasinee Sinawat, M.D. · Department of Ophthalmology, Faculty of Medicine, Khon Kaen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01724385 on ClinicalTrials.gov